Great Basin secures $9.5 million in funding, 3/13

Create PDF

March 2013—Great Basin Corp., a privately held molecular diagnostics company that develops sample-to-result solutions, has raised $9.5 million in series B funding. The funding was led by private investors and will be used to expand manufacturing, fund research and development, and expand global commercialization efforts.

The company received FDA clearance in May for its first product, a molecular diagnostic test for toxigenic Clostridium difficile, and launched the platform in November.

Specifically, the funding will allow Great Basin to expedite menu expansion, including three clinical trials this year. Great Basin intends to begin clinical trials for its Staph ID/R assay in the first quarter of the year. The assay is an automated DNA multiplex test that identifies major pathogenic strains of Staphylococcus as well as the methicillin-resistance determinant gene, mecA.

Great Basin Corp., 801-990-1055